Nurix Therapeutics $175 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Biodesix $55 million follow-on offering
The common stock is listed on the Nasdaq Global Market
Adagene $100 million at-the-market offering
We advised Adagene on the offering
Stoke Therapeutics $125 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Select Market
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Haleon $3.1 billion secondary offering
The shares are listed on the NYSE
Smith+Nephew $1 billion notes offering
We advised the issuer on the SEC-registered offering
Avid Bioservices $160 million convertible senior notes offering
The convertible notes are due 2029
REGENXBIO $140 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market